Nelson W L, Fraunfelder F T, Sills J M, Arrowsmith J B, Kuritsky J N
Am J Ophthalmol. 1986 Nov 15;102(5):606-11. doi: 10.1016/0002-9394(86)90532-5.
Between September 1978 and December 1985, 450 case reports of serious respiratory and cardiovascular events and 32 case reports of death attributed to ophthalmic timolol were received by the United States Food and Drug Administration and the National Registry of Drug-Induced Ocular Side Effects. Two hundred sixty-seven patients (55%) experienced a cardiac arrhythmia or a bronchospasm-related event. The median age was 68 years (n = 365). Fifty-five percent of the patients were women and 45% were men (n = 41). Of the 212 persons for whom medical history was provided, 129 (61%) had respiratory disease, 65 (31%) had cardiovascular disease, 13 (6%) had other illnesses, and five (2%) had no underlying illness. Of the 318 patients for whom data on duration of drug use were available 106 (33%) experienced their adverse event within one week of beginning timolol therapy: 73 (23%) had their events on the first day of therapy. Of 192 patients for whom information was available 177 (92%) improved after the drug was discontinued.
1978年9月至1985年12月期间，美国食品药品监督管理局和药物性眼部副作用国家登记处共收到450例严重呼吸和心血管事件的病例报告以及32例归因于眼科用噻吗洛尔的死亡病例报告。267名患者（55%）经历了心律失常或支气管痉挛相关事件。中位年龄为68岁（n = 365）。55%的患者为女性，45%为男性（n = 41）。在提供了病史的212人中，129人（61%）患有呼吸系统疾病，65人（31%）患有心血管疾病，13人（6%）患有其他疾病，5人（2%）无基础疾病。在可获得用药持续时间数据的318名患者中，106人（33%）在开始噻吗洛尔治疗的一周内出现不良事件：73人（23%）在治疗第一天出现事件。在可获得信息的192名患者中，177人（92%）在停药后病情好转。
